October 18th, 2023

Modus Health is excited to announce the next generation of Stepwatch, Stepwatch 5. It is half the weight and size of StepWatch 4 with greater memory and functions. StepWatch 5 is both FDA listed and CE marked for use in clinical trials and clinical care. It has been designed to scale quickly as it is much faster to manufacturer than past StepWatch models. At Modus Health, we will continue to improve to meet your needs

July 12, 2022

PharmStars, the pharma-focused accelerator for digital health startups, announces the graduation of 11 startups from its Spring 2022 program. The graduates successfully completed the 10-week PharmaU program, which culminated with the Showcase Event held June 8-10 in Boston. The Showcase Event brought together the participating startups and PharmStars’ seven innovation-minded pharma members.

11 digital health startups have successfully completed PharmStars’ pharma-focused accelerator program

Boston, Massachusetts – PharmStars, the pharma-focused accelerator for digital health startups, is delighted to announce the graduation of 11 startups from its Spring 2022 program. The graduates successfully completed the 10-week PharmaU program, which culminated with the Showcase Event held June 8-10 in Boston. The Showcase Event brought together the participating startups and PharmStars’ seven innovation-minded pharma members.

PharmStars focuses on bridging the “pharma-startup gap” by helping pharma and startups overcome partnership barriers. PharmStars’ unique PharmaU program provides education and mentorship to help startups and pharma partner more effectively.

The newest cohort was selected in March 2022 following a competitive application process. Each startup offers a novel digital health solution related to the theme of “Innovations in Neurological Disease.” Their products represent a diverse array of digital health solutions, including digital biomarkers, digital therapeutics, remote patient monitoring, and patient engagement tools.

At the Showcase Event, startups presented their solutions and participated in one-on-one meetings with representative of PharmStars’ pharma members. Participating startups said that the Showcase Event was extremely impactful.

“Normally, it takes years from an initial meeting to a serious conversation with a pharma company. In one day, we have the attention of six pharma companies specifically interested in what we can do! The opportunity is enormous,” said the CEO of one of the startups.

The CEO of another participating startup said, “We are an early-stage startup. For us, to have an opportunity to showcase our company to major pharma companies…is an occasion that we had not even considered possible. It’s not only the pharma companies’ audience but, most importantly, the ‘right’ people within pharma attended the event.”

The following 11 digital health startups successfully completed the PharmStars accelerator:

  • Accexible (Barcelona, Spain): Rapid, remote, device-agnostic speech biomarkers foraccurate screening and monitoring of mild cognitive impairment (MCI) and earlydementia.
  • BeCare Link (Rumson, NJ): Gamified, mobile app for the remote, objective, andquantitative assessment of neurological function and decline using AI.
  • Deliberate AI (New York, NY): Multi-modal diagnostics platform and machine learning model for the analysis of behavioral and physiological biomarkers to detect symptoms and monitor patients with psychiatric and neurological conditions.
  • Head Diagnostics Ltd (Dublin, Ireland): A novel, hand-held medical device measuring ocular microtremor (OMT) enabling the rapid, non-invasive assessment of Parkinson’s disease.
  • HealthQb Technologies (Vancouver BC, Canada): A biopsychosocial behavior modification system for pain and chronic disease which objectively measures, prioritizes, and targets a patient’s personalized “hidden” psycho-social factors that contribute to their persistent illness.
  • Modus Health (Edmonds, WA): Wearable and validated digital endpoints for measuring real-world walking quantity, intensity, and duration, with demonstrated superior accuracy compared to other wearable mobility assessment tools.
  • Neuroventis (Brussels, Belgium): Neurological patient and HCP engagement platform offering services and programs to deliver optimal patient outcomes, improved medication adherence, and generation of real-world data.
  • Orbit Health (Munich, Germany): AI-enabled platform using commercially available smartwatches to offer objective, convenient, minute-by-minute information on motor symptoms and treatment response in Parkinson’s patients, in real-world settings.
  • REACT Neuro (Cambridge, MA): Self-administered, in home, virtual reality platform for quantitative, comprehensive, and objective neurocognitive assessments.
  • Vistim Labs Inc. (Salt Lake City, UT): Novel functional EEG-based, AI-enabled cognitive assessment collecting real-time stimulated brain activity to enable objective measurement of early, previously imperceivable changes in cognitive function.
  • WKD.SMRT (Cambridge, MA): Pre-configured, video-based and sensor-based, in-home platform that passively, ambiently, and continuously collects objective, high-quality, real-world data on motor and functional performance.

PharmStars is accepting applications until July 16 for its Fall 2022 cohort, themed “Innovations in Real-World Evidence.” For digital health startups interested in participating, information on dates, deadlines, and the application form is available on the PharmStars website.

PharmStars 2022 membership is now open to a limited number of additional pharma and biotech companies.

About PharmStars PharmStarsTM is the member-based, pharma-focused accelerator for digital health startups. Through our extensive expertise across pharma, startups, digital health, and innovation, we understand the challenges that pharma and startups face when seeking to collaborate. Our PharmaUTM program supports digital health startups and our pharma members in “bridging the pharma-startup gap,” leading to greater success and faster adoption of “beyond the molecule” solutions for patients.

November 18, 2021


Adapttech licenses IP to industry-leading mobility tracking software to improve patient mobility outcomes.

BIRMINGHAM, UK and PORTO, PORTUGAL – Biomedical scale-up Adapttech, today announced that it has licensed IP from leading activity-monitoring company, Modus Health. Adapttech will now integrate and adapt Modus’ StepWatch™ software, the gold standard for accurate motion monitoring, into its future product designs and patient outcome models.

Modus technology has been validated in over 500 peer-reviewed publications, with StepWatch being used as the gold standard by researchers and companies such as Google, Fitbit, and Samsung Digital Health for measuring the accuracy of their fitness monitors.

Adapttech promotes patient mobility by creating devices that leverage key health data points to deliver improved patient outcomes. Adapttech’s first product, the INSIGHT System, is designed to improve the fitting process of lower-limb prostheses for amputees; this new deal will see the company expand its market focus in patient outcomes management through new hardware devices, apps, data servers, AI-supported analysis, and professional reporting for insurance payers and healthcare professionals.  

Frederico Carpinteiro, CEO, Adapttech, said: “Our partnership with Modus Health supports the development of new solutions based on their industry leading technology and our market reach, this will enable Adapttech to better help our clinical customers improve the mobility of their patients. We have an exciting pipeline of products in development which are undergoing user-testing ahead of being released next year – our first product will showcase the successful incorporation of StepWatch technology.”

StepWatch™ is an FDA-listed medical device which accurately measures more than 20 key points of information in the wearer’s walking pattern, including cadence, daily steps, walking duration, and more. This data can be used to assess patient conditions, even beyond mobility, and support prescribed solutions.

Teri Chou, CEO, Modus Health, said: “StepWatch technology has been featured in multiple peer-reviewed journals that address over 30 patient conditions, we have seen great patient outcomes in these studies and look forward to benefiting from the market scale commercialization that this relationship with Adapttech will deliver.”

Adapttech will release new technology in 2022 incorporating licensed IP from Modus Health.


Adapttech is a biomedical company focused on developing technologies that empower healthcare providers to help people with physical limitations to improve their quality of life. In 2021, the company closed a £2 million funding round. The round was supported by existing investors including the MEIF Proof of Concept & Early Stage Fund, Midlands Engine Investment Fund; Bionova Capital, and new investors including ACF Investors, Wealth Club and Wren Capital.

April 5, 2021

DCH Health System First in Nation to Use New Rehabilitation Technology

(Tuscaloosa, Ala.) DCH Health System will be the first in the United States to implement Modus Health’s patient mobility monitoring and management software.

Patients use a highly accurate wearable called StepWatch™ to track their mobility. Providers such as physical therapists are then able to use Modus’ Clinical Care software to assess progress. The trackers and software will be used with patients at the DCH Rehabilitation Pavilion.

“In the first year of this partnership, more than 100 patients will receive personalized mobility monitoring and management,” said Nathan Buckalew, director of the DCH Rehabilitation Pavilion. “This data will be extremely helpful in tracking a patient’s progress throughout recovery.”

The metrics provided by Modus Health’s technology have been shown to help predict hospital length of stay, readmissions and disease progression among varying types of patients. 

About Modus

Modus Health is a medical device and software company based in Seattle, Wash. Modus Health is focused on becoming the premier wearable medical device company in global usage where mobility matters. For more information about the company, visit

About DCH

DCH Health System is a public, not-for-profit health system located in West Alabama. For nearly 100 years, DCH has provided quality health care to the people of West Alabama. DCH Health System includes DCH Regional Medical Center, Northport Medical Center and Fayette Medical Center. The DCH Rehabilitation Pavilion is located on the Northport Medical Center campus. For more about DCH, visit

February 10, 2020

SEATTLE, USA – (MODUS HEALTH) has been selected by Startup Grind, powered by Google for Startups, for the Startup Exhibition in the Grind category at the 2020 Startup Grind Global Conference held February 11-12th in Silicon Valley.

About Modus Health

Modus is a medical device and software company focused on changing healthcare by facilitating best-in-class walking monitoring solutions. Its wearable, StepWatch, is the gold standard in measuring walking, as proven in over 500 journal articles. Our real-world outcomes facilitate improved health for the patient and improved efficiency of resources for clinics. As a result, StepWatch will be the dominant medical device wearable globally where ever mobility matters.

About Startup Grind

Startup Grind is the largest independent startup community, actively educating, inspiring, and connecting 3,500,000 founders in more than 600 chapters globally. Founded in Silicon Valley, we nurture startup ecosystems in 125+ countries through events, media, and partnerships with organizations such as Google for Startups. Our local monthly events feature successful local founders, innovators, educators and investors who share lessons learned on the road to building great companies. Startup Grind also hosts two flagship conferences annually — the Global Conferenceand Europe Conference. To date, Startup Grind has helped millions of entrepreneurs find mentorship, connect to partners and hires, pursue funding, and reach new users. Learn more at

July 29, 2019

Modus Health earns first clinical care contract with CatoSenteret in Norway. CatoSenteret will be working with Modus Health in the development of its Acute Care System in order to encourage increased patient mobility during their inpatient stay. Modus Health’s CEO, Teri Chou, states “Jan and his team at CatoSenteret are true innovators who are willing to work through the barriers of change for the benefit of their patients. We are excited to partner with them on this critical project.”

The goal of CatoSenteret is to improve patient health before they leave the hospital. Increased mobility plays a key role in achieving this outcome. Several publications have already shown that increased ambulation as measured by StepWatch is associated with reduced length of stay (McCullagh, 2016), risk of readmission (Fisher, 2016), and improved outcomes (Hornby, 2015). In addition, a study using many different activity monitors during inpatient care found that only StepWatch detected steps in every patient (Treacy, 2017). StepWatch has also been demonstrated to be the only accurate monitor for measuring walking in daily life (Toth, 2018). Modus Health is leveraging StepWatch’s unique accuracy and proven digital biomarkers to improve healthcare through cost-effective platforms. Modus Health’s goal is to become integrated into routine clinical care worldwide.

Jan Nordvik, CEO of the Norwegian rehabilitation center, says of the new collaboration: “The StepWatch is the most precise activity sensor that we are aware of. In clinical work this level of precision is a necessity. In addition, Teri and the Modus Health group are a great innovative team that we are certain will help us to move into a new generation of health care systems where sensor technology is essential to proving the quality of the care for our patients”.


R. McCullagh, C. Dillon, D. Dahly, N. F. Horgan, S. Timmons. Walking in hospital is associated with a shorter length of stay in older medical inpatients. Physiological measurement 2016; 37(10):1872-1884.

S. R. Fisher, J. E. Graham, K. J. Ottenbacher, R. Deer, G. V. Ostir. Inpatient Walking Activity to Predict Readmission in Older Adults. Arch Phys Med Rehabil 2016; 97(9 Suppl):S226-31.

T. G. Hornby, C. L. Holleran, A. L. Leddy, et al. Feasibility of Focused Stepping Practice During Inpatient Rehabilitation Poststroke and Potential Contributions to Mobility Outcomes. Neurorehabil Neural Repair 2015; 29(10):923-32.

D. Treacy, L. Hassett, K. Schurr, S. Chagpar, S. S. Paul, C. Sherrington. Validity of Different Activity Monitors to Count Steps in an Inpatient Rehabilitation Setting. Phys Ther 2017; 97(5):581-588.

L. P. Toth, S. Park, C. M. Springer, M. D. Feyerabend, J. A. Steeves, D. R. Bassett. Video-Recorded Validation of Wearable Step Counters under Free-living Conditions. Med Sci Sports Exerc 2018.

March 27, 2019

Modus Health was one of four companies interviewed in Clinical OMICs Wearable Data Revolution. Our unique walking algorithm has demonstrated digital biomarkers in many patient conditions (e.g. COPD, CMT, inpatient care, post-stroke, CMT, DMD) for applications in pharmaceutical trials and clinical care. Feel free to contact [email protected] for more information.

July 1, 2018

Modus Health hires Chris Green as its CTO. Chris was the first employee of CoverMyMeds as the software and systems architect in 2008.  CoverMyMeds sold for $1.1 billion in 2017. As one of the original founding employees of Modus Health from 2013 – 2015, Chris successfully transitioned StepWatch to a new manufacture and led quality control and product development. From 2015-2016, Chris was acting CTO of a presidential candidate’s campaign and then continued running his own consulting business. “We are thrilled to have Chris back and elevated to the position he deserves. CTO reflects his level of performance, effort, and skill. Together we are accomplishing what much larger companies are not, and I cannot wait for the world to see what we can do,” says Modus CEO, Teri Chou.

December 1, 2017

Following earning Modus Health’s first pharmaceutical contract, Dr. Teri Chou gets promoted from Chief Scientific Officer to CEO. Dr. Chou was a founding employee of Modus Health in 2013 as Director of Clinical Research. She stayed during the restructure of 2016 as the remaining employee. During this time, she earned an NIH grant with Harvard Medical School that provided funds for creating the StepWatch 4 prototype. This prototype was used to earn the first pharmaceutical contract with Pfizer and investment funding for product development and company growth.